(Q34212195)

31 July 2017

1 reference

title

Polycystic ovary syndrome and ovulation induction. (English)

1 reference

polycystic ovary syndrome

31 July 2017

main subject

1 reference

1 reference

Phipps WR

1

1 reference

31 July 2017

publication date

1 March 2001

1 reference

Obstetrics and Gynecology Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

28

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

165-182

1 reference

Clomiphene citrate: the case for a monoisomeric preparation

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Time interval from human chorionic gonadotrophin (HCG) injection to follicular rupture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

1 reference

7 January 2021

The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Exogenous estrogen therapy for treatment of clomiphene citrate-induced cervical mucus abnormalities: is it effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Hypothalamic-pituitary-adrenocortical function during long-term low-dose dexamethasone therapy in hyperandrogenized women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Diagnosis of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinica

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A randomized study of dexamethasone in ovulation induction with clomiphene citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Risk of ovarian cancer after treatment for infertility

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Increased monozygotic twinning rate after ovulation induction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Relationship of follicle number and other factors to fecundability and multiple pregnancy in clomiphene citrate-induced intrauterine insemination cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Insulin-lowering therapeutic modalities for polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: a comparative, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

1 reference

7 January 2021

A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Effects of weight loss on the hormonal profile in obese, infertile women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

The use of cortisone in follicular phase disturbances

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Pathophysiology of reproductive failure after clomiphene-induced ovulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

An extended regimen of clomiphene citrate in women unresponsive to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Hyperprolactinemia in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Clinical and biochemical evaluation of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Low dose follicle-stimulating hormone therapy for polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Single-dose pharmacokinetics of clomiphene citrate in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Ovarian tumors in a cohort of infertile women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

Polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970192-3

7 January 2021

10.1016/S0889-8545(05)70192-3

Identifiers

DOI

1 reference

31 July 2017

1 reference